Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
2.380
+0.190 (8.68%)
At close: Jun 18, 2025, 4:00 PM
2.400
+0.020 (0.84%)
Pre-market: Jun 20, 2025, 8:47 AM EDT
Compass Therapeutics Revenue
Compass Therapeutics had revenue of $850.00K in the twelve months ending March 31, 2025. In the year 2024, Compass Therapeutics had annual revenue of $850.00K.
Revenue (ttm)
$850.00K
Revenue Growth
n/a
P/S Ratio
387.19
Revenue / Employee
$24,286
Employees
35
Market Cap
329.11M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CMPX News
- 23 days ago - Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha
- 6 weeks ago - Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewsWire
- 7 weeks ago - Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 2 months ago - Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer - GlobeNewsWire
- 2 months ago - Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewsWire
- 2 months ago - Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - GlobeNewsWire